2Fliser D, Pacini G, Engelleiter R, et al. Insulin resistance and hyper insulin emia a real ready present in patients with in cipient renal disease. Kidney Int 1998;53(5): 1343 - 1347.
3Guan Y, Breyer MD. Peroxisome proliferator - activated receptors(PPARs) :Novel therapeutic targets in renal disease. Kidney Int 2001 ;60(1) : 14 - 30.
4Torra 1, Pineda, Staels B, et al. Pleiotropic action of peroxisome proliferator - activated receptors in lipid metabolism and atherosclerosis 2002 ; 22(5) : 717 - 726.
5Sunder MD, Robert R, et al. PPAR agonists in health and disease: A pathophysiologic and clinical overview 2002 ; 9 (4) : 285 -302.
6Winer N,Sowers JR, Weber MA. The effect of antihypertensive drugs on vascular compliance. Curr Hypertens Rep 2001; 3(4)297 - 304.
7Diep QN, El Mabrouk M, Cohn JS, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin Ⅱ - infused rats:role of peroxisome proliferator - activated receptor-gamma. Circulation 2002; 105(19) :2296 - 2302.
8Ricote M, Valledor AF, Glass CK. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atheroselerosis. Arterioscler Thromb Vase Biol 2004;24(2) :230- 239.
9Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002;2(10):748-759.
